	Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses a subgroup analysis of the phase III CLARINET study.

gastrointestinal and pancreatic neuroendocrine tumors 

	The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic 

GEP-NETs), in December 2013. In the study, treatment with the somatostatin analog lanreotide improved progression-free survival by 53% compared with placebo for patients with grade 1 or 2 GEP-NETs.

	The subgroup analysis took a closer look at the risks, benefits, and outcomes for patients taking lanreotide for the treatment of pancreatic neuroendocrine tumors (pNETs). Phan says the results of the analysis showed that the benefits of taking lanreotide as a first-line treatment outweighed the risks, and that the drug improved progression-free survival.

View more from the 2015 GI Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastrointestinal Cancers Symposium (ASCO GI)

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.) 

Dr. Alexandria Phan on a CLARINET Study Subgroup Analysis